Investigator Sponsored Studies, grants and sponsorships
Vertex Pharmaceuticals supports independent research and innovative studies focused on cystic fibrosis, sickle cell disease, pain, and related serious diseases.
Funder: Vertex Pharmaceuticals
Due Dates: Rolling (ISS, grants, sponsorships) | 2026 (next cycle for VIA and RIA Awards, Circle of Care)
Funding Amounts: Up to $750,000 USD per project (VIA and Independent RIA); up to $125,000 USD (Mentored RIA); no fixed cap for ISS or general grants, but budget must be justified and overhead should not exceed 35%.
Summary: Supports independent research, education, and community initiatives in serious diseases such as cystic fibrosis, sickle cell disease, pain, and others.
Key Information: Most opportunities accept applications on a rolling basis; specific CF award programs have annual cycles.
Description
Vertex Pharmaceuticals offers a broad range of funding opportunities for independent investigators, healthcare professionals, and organizations to advance scientific research, education, and community programs in areas of serious disease. The primary focus is on cystic fibrosis, sickle cell disease, beta thalassemia, IgA nephropathy, pain, and related conditions. Funding is available for investigator-sponsored studies (ISS), educational grants, patient advocacy initiatives, sponsorships, and specialized award programs.
Vertex supports:
- Independent clinical and nonclinical research (ISS)
- Medical education (accredited and non-accredited)
- Patient and caregiver education and advocacy
- Organizational sponsorships and corporate memberships
- Specialized awards for cystic fibrosis researchers (VIA, RIA, Circle of Care)
Funding is provided to organizations, not individuals, and is intended for new, scientifically rigorous projects that align with Vertex’s research interests.
